Clinical Trials Logo

Filter by:
  • Active, not recruiting  
  • Page [1] ·  Next »
NCT ID: NCT06467877 Active, not recruiting - Hypercalcemia Clinical Trials

Causes, Characteristics and Treatment of Hypercalcemia in the Emergency Room of a German Hospital

Start date: January 1, 2010
Phase:
Study type: Observational

Patients with hypercalcemia were identified in the patient population of a German emergency department during a 11 year time period and studied regarding reproducibility of elevated calcium values, causes of hypercalcemia, symptoms. acute renal injury, mortality and treatment response.

NCT ID: NCT06464341 Active, not recruiting - Breast Cancer Clinical Trials

Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study

ICARO
Start date: May 4, 2023
Phase:
Study type: Observational

The purposes of this multicenter retrospective cohort study are to determine the residual nodal burden in patients with isolated tumor cells detected in the SLN or the clipped node after NAC and to determine oncologic outcomes in this group of patients after ALND or nodal RT or observation.

NCT ID: NCT06464289 Active, not recruiting - Rib Fractures Clinical Trials

Surgical Stabilisation of Rib Fractures in Non-ventilated Patients

Start date: April 13, 2024
Phase:
Study type: Observational

The aim of the study is to investigate the effect of surgical stabilisation of rib fractures on clinical outcomes in patients that are not dependent on mechanical ventilation at the time of the treatment decision. To this end, data on all eligible patients will be extracted from the TraumaRegister® DGU. Baseline demographics will be analysed using descriptive statistics. Propensity matching will be conducted between the operative cohort (receiving SSRF by any technique) and the conservative cohort (not receiving SSRF). The effect of SSRF on the outcome variables will then be assessed using appropriate statistical tests.

NCT ID: NCT06450808 Active, not recruiting - Clinical trials for Pharmacokinetic Parameters

The Microalga Phaeodactylum Tricornutum a Potential Fish Substitute?- Pharmacokinetic Study

MikroFisch
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

In a cross-over design, pestos enriched with different levels of the microalgae Phaeodactylumtricornutum (2-3-4%) will be tested. The bioavailability of long-chain omega-3 fatty acids, in particular EPA and carotenoids, will be analysed in blood plasma postprandially within two days after a single dose. Pharmacokinetic parameters will be calculated from the measured data. The aim of the study is to gain insight into the bioavailability of selected microalgae constituents and the acceptance of microalgae pesto.

NCT ID: NCT06370858 Active, not recruiting - Crohn Disease Clinical Trials

RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease

Start date: July 24, 2023
Phase: Phase 2
Study type: Interventional

This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is designed to evaluate the safety and efficacy of RVT-3101 in adult participants with moderate to severe active Crohn's disease.

NCT ID: NCT06367543 Active, not recruiting - Stroke Clinical Trials

Guideline-recommended Basic Parameter Adherence in Neurocritical Care Patients

NORMONICU
Start date: November 30, 2022
Phase:
Study type: Observational

The aim of the planned study project is to assess the current situation regarding the treatment of patients with severe stroke at the neuro-critical care unit. Specifically, determination of whether the target parameters recommended in the guidelines for temperature, systolic blood pressure, mean arterial blood pressure, blood glucose, arterial oxygen partial pressure and arterial carbon dioxide partial pressure had to be maintained. From the planned data analysis, the need for the introduction of cerebrovascular bundles can be derived and planned.

NCT ID: NCT06365827 Active, not recruiting - Acute Kidney Injury Clinical Trials

Perioperatively Assessed Biomarker I-FABP Level for Prediction of Acute Mesenteric Ischemia and Its Correlation With Acute Kidney Injury, Followed by Extracorporeal Circulation (aMIKI)

aMIKI
Start date: March 1, 2022
Phase:
Study type: Observational [Patient Registry]

Acute mesenteric ischemia (AMI) is a severe condition that might occur after cardiovascular surgery. Several risk factors for AMI, such as multimorbidity, the use of vasopressors, and an increase in inflammatory markers have been identified in the past. However, these risk factors also seem to influence the blood and urine levels of I-FABP. This prospective pilot study intends to evaluate the value of perioperatively assessed I-FABP levels and to correlate these values with clinical or angiographic findings in mesenteric ischemia to improve a standardised diagnosis.

NCT ID: NCT06360081 Active, not recruiting - Healthy Clinical Trials

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Start date: April 26, 2024
Phase: Phase 1
Study type: Interventional

The main objective of this trial is to establish the bioequivalence of zongertinib tablet from manufacturer 1 (Test, T) compared with zongertinib tablet from manufacturer 2 (reference, R) following oral administration.

NCT ID: NCT06343571 Active, not recruiting - Cochlear Implants Clinical Trials

Longitudinal Outcomes in MED-EL Cochlear Implant Recipients Using a FLEX Electrode

LOTOS
Start date: April 17, 2024
Phase:
Study type: Observational

This retrospective study aims at analysing data from clinical routine as anonymized data sets. The study aims at analysing clinical data from MED-EL Cochlear Implant (CI) recipients using a FLEX electrode array.

NCT ID: NCT06311383 Active, not recruiting - Breast Cancer Clinical Trials

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

RIBANNA
Start date: October 9, 2017
Phase:
Study type: Observational

This is a non-interventional observational study conducted in Germany to evaluate the real-world effectiveness, tolerability, safety, and quality of life in patients with locally advanced/metastatic HR+/HER2- breast cancer treated with one of the following 1st line treatments: Ribociclib + AI/FUL, or endocrine monotherapy, or chemotherapy